Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Steroid use during tonsillectomy does not raise excessive bleeding risk

Children who are given dexamethasone during tonsillectomy are not more likely to experience excessive bleeding after surgery than those who do not receive the steroid perioperatively, study findings suggest.

2 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

29 Sep 2012

Nottingham expert to study impact of gluten intolerance on patients in the UK

A University of Nottingham expert has been awarded -80,000 by two national charities to study the impact of gluten intolerance on patients in the UK.

27 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Increasing doses of radium chloride effective, tolerated in prostate cancer

Radium chloride treatment has dose-dependent beneficial effects on health outcomes in patients with castration-resistant prostate cancer and bone metastases, report researchers.

26 Sep 2012

Dexamethasone use during tonsillectomy not associated with excessive bleeding in children

Tonsillectomy is exceedingly common, with a reported increase in tonsillectomy rates in children younger than 15 years from 287,000 to 530,000 per year over the past decade. Although safe, adenotonsillectomy can result in significant complications, such as aspiration and bleeding. Complications are infrequent, but because tonsillectomy is so common, the absolute number of children experiencing tonsillectomy complications is formidable.

26 Sep 2012

Extended release exenatide outperforms twice daily regimen

Once-weekly extended-release exenatide is a more effective treatment than twice-daily exenatide at improving glucose control among Japanese individuals with diabetes, report researchers.

24 Sep 2012

FDA approves Mylan's ANDA for generic Antivert

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg and 50 mg.

21 Sep 2012

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.

21 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Many children with ASD also experience anxiety, GI problems and atypical sensory responses

One in 88 children has been diagnosed with an autism spectrum disorder (ASD) in the United States, according to the Centers for Disease Control and Prevention. A new study by a University of Missouri researcher found that many children with ASD also experience anxiety, chronic gastrointestinal (GI) problems and atypical sensory responses, which are heightened reactions to light, sound or particular textures.

20 Sep 2012

New 24/7 Cardiologist program now available at ProMedica Toledo Hospital

ProMedica Toledo Hospital is the only hospital in northwest Ohio with a cardiologist on duty 24 hours a day, seven days a week, to treat patients who may be experiencing a heart attack.

20 Sep 2012

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

The p53 gene plays a key role in the prevention of cancer, by blocking cell growth and triggering programmed cell death or apoptosis. If, however, p53 has mutated and become defective, the cancer cells can acquire the ability to evade apoptosis and become more resistant to therapy.

20 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

Nausea News and Research

Further Reading

Steroid use during tonsillectomy does not raise excessive bleeding risk

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

Nottingham expert to study impact of gluten intolerance on patients in the UK

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Increasing doses of radium chloride effective, tolerated in prostate cancer

Dexamethasone use during tonsillectomy not associated with excessive bleeding in children

Extended release exenatide outperforms twice daily regimen

FDA approves Mylan's ANDA for generic Antivert

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

Boehringer Ingelheim files MAA with EMA for afatinib approval

Many children with ASD also experience anxiety, GI problems and atypical sensory responses

New 24/7 Cardiologist program now available at ProMedica Toledo Hospital

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News